Kumar, Raminder · Drugs · 2008 · DOI
This review looked at studies testing modafinil, a medication that promotes wakefulness, in different conditions including sleep disorders and fatigue-related illnesses. The authors found that modafinil works well for approved conditions like narcolepsy and sleep apnea, but studies testing it for chronic fatigue syndrome were very small and gave unclear results. The medication can cause side effects like insomnia, headaches, and appetite loss, and may interact with other drugs.
For ME/CFS patients and researchers, this review is important because it systematically evaluates modafinil—a drug sometimes used off-label for fatigue—and explicitly acknowledges that existing trials in chronic fatigue syndrome are too small and inconsistent to draw conclusions. This highlights a critical gap: modafinil's efficacy and safety in ME/CFS remain unproven, and larger, well-designed studies are needed before clinical recommendations can be made.
This review does not establish that modafinil is effective for chronic fatigue syndrome, Parkinson's disease, or post-polio fatigue—the authors explicitly state that all trials in these conditions had extremely small sample sizes and inconsistent results. It also does not prove that modafinil's effects observed in other conditions (like narcolepsy) will translate to ME/CFS, which has a distinct pathophysiology. The substantial placebo effects observed in conditions like traumatic brain injury and depression further complicate interpretation in fatigue-related illnesses.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →